Navigation Links
Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
Date:9/3/2008

der (with or without cardiovascular risk factor) or above 70 years of age with at least one additional cardiovascular risk factor (hypertension, diabetes, previous cerebrovascular event, left atrium size greater than 50 mm or left ventricular ejection fraction lower than 40%). Patients were randomized to receive Multaq(R) 400 mg BID or placebo, with a maximum follow-up of 30 months.

The ATHENA study objectives were to show a potential benefit of Multaq(R) on the primary composite endpoint of all-cause mortality combined with cardiovascular hospitalization as compared to placebo. The pre-specified secondary endpoints were death from any cause, cardiovascular death and hospitalization for cardiovascular reasons. The pre-specified safety endpoint was the incidence of treatment emergent adverse events (between first study drug intake and last study drug intake plus 10 days) including: all adverse events, serious adverse events, adverse events leading to study drug discontinuation.

The ATHENA stroke post-hoc analysis on non-pre-specified secondary endpoint was conducted in order to confirm the consistent benefit of Multaq in atrial fibrillation or atrial flutter patients in reducing major cardiovascular complications like stroke, which is a leading cause of cardiovascular hospitalization or death in this patient population.

About Multaq(R) (dronedarone)

Multaq(R) is an investigational treatment and the only anti-arrhythmic drug (AAD) to have shown a significant reduction in morbidity and mortality in atrial fibrillation /atrial flutter patients with a favourable safety profile as evidenced by a low incidence of pro-arrhythmia (including torsades de pointes) and extra-cardiac organ toxicity. Multaq(R), discovered and developed by sanofi-aventis, has been studied in a clinical development program including more than 7,000 patients. Multaq(R) is one of the major therapeutic innovations for atrial fibrillation in the last twenty years.

Mult
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
2. Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
3. Addrenex Pharmaceuticals New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation
4. Blood Pressure Lowering Effect of Hypertension Treatment Device Further Validated in New Studies
5. Published Guidelines Further Support Use of Bioimpedance Measurement Technology for Early Assessment of Lymphedema
6. Further Clinical Testing of BZL101 in Advanced Breast Cancer Demonstrates Favorable Efficacy and Toxicity Profiles
7. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
8. New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients
9. Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals Nicotinic Alpha-7 Agonist, MEM 3454
10. GlaxoSmithKline Reports Further Progress of Oncology Portfolio
11. Arpida Provides Further Comments on the Pivotal Phase III Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014  Alimera Sciences, Inc. (NASDAQ: ... the research, development and commercialization of prescription ophthalmic pharmaceuticals, ... of fiscal year 2014 financial results after the market ... call will follow on the same day at 4:30 ... be hosted by Dan Myers , President and ...
(Date:7/24/2014)... July 24, 2014  Kinex Pharmaceuticals announced the receipt ... Company,s KX2-391 Ointment for the commencement of a Phase ... Company,s third IND to be allowed by the US ... is a synthetic, orally active and highly selective inhibitor ... promotes the induction of p53, G2/M arrest of proliferating ...
(Date:7/24/2014)... CAMPBELL, Calif. , July 24, 2014 /PRNewswire/ ... the development of novel interventional devices to facilitate ... United States Patent and Trademark Office has issued ... core technology behind the company,s Lazarus Cover TM ... The Lazarus ReCover is a single-component stent-retriever ...
Breaking Medicine Technology:Alimera Sciences To Release Second Quarter 2014 Results 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 3Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 4Lazarus Effect Receives Notice of Allowance for New US Patent Covering Core Protection Technology 2
... 26 Brainlab announced the availability of ExacTrac® Infrared Monitoring, ... during radiation therapy treatments, at the American Association of Physicists in ... , , ... tool used by many cancer care centers for patient setup; however, ...
... ,, ROCKVILLE, Md. , July 26 Sequella, Inc., ... announced today the publication of studies in the scientific journal Antimicrobial ... for the treatment of TB, and TMC207, Tibotec lead TB drug candidate: ... Reddy, V.M., L. ...
Cached Medicine Technology:Brainlab Offers Real-Time Monitoring for IGRT 2Two New Tuberculosis (TB) Drugs Show Significant Synergy In Vitro 2Two New Tuberculosis (TB) Drugs Show Significant Synergy In Vitro 3
(Date:7/24/2014)... (PRWEB) July 25, 2014 Voted one ... of the global clients, BellasDress focuses on providing its ... useful fashion information. Recently, the company has announced its ... in the new range is created according to the ... big discounts, up to 68% off. , As a ...
(Date:7/24/2014)... 2014 Four Seasons Resort Maui ... its $3 million renovation of the famed Maile suite ... suites, just in time to welcome summer guests vacationing ... direction from the internationally-acclaimed BraytonHughes Design Studios, San Francisco ... property and the largest in Hawaii—received a complete re-envisioning. ...
(Date:7/24/2014)... HealthDay Reporter THURSDAY, July 24, ... may be dead wrong, according to a small study that asked ... with 33 boys between the ages of 14 and 16, researchers ... for the closeness and trust. Very few boasted about sexual conquests ... with a girl. "In our culture, we have lots of ...
(Date:7/24/2014)... the risk for head and neck cancer (HNC). Evidence suggests ... the risk of HNC in patients with DM has not ... sixth most common type of cancer. It accounts for about ... new cancer cases and 350,000 cancer deaths worldwide each year. ... to examine the risk of HNC in patients with DM. ...
(Date:7/24/2014)... This year the Walk to End ... Jackson National Life, will be held on Saturday, September 20 ... Kids Fun Run at 7:50 am, the untimed 5k Run ... , “The Walk to End Alzheimer’s unites the entire community ... fight against this devastating disease, “stated Linda Mitchell, CEO and ...
Breaking Medicine News(10 mins):Health News:BellasDress Helps Brides Get High End Wedding Dresses for Their Romantic Weddings 2Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 2Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 3Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 4Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 5Health News:Teenage Boys Want Intimacy, Not Just Sex, Survey Finds 2Health News:Teenage Boys Want Intimacy, Not Just Sex, Survey Finds 3Health News:Alzheimer's Association Walk to End Alzheimer's Steps Off Saturday, September 20 in Denver 2Health News:Alzheimer's Association Walk to End Alzheimer's Steps Off Saturday, September 20 in Denver 3
... -- Despite growing concern about the effects of media ... to be produced and marketed to them. An Indiana ... to their enjoyment of such programs and their characters. ... Media Psychology , Andrew J. Weaver, an assistant ...
... Wong, one of the nation,s foremost experts on aging, ... on Aging of the National Institutes of Health to ... the grant for a longitudinal aging study she and ... will collect current data from thousands of participants and ...
... primary language is not English, patient navigators may help improve ... the May 23 issue of Archives of Internal Medicine ... of the journal,s Health Care Reform series. According to ... country,s main causes of cancer deaths. "Nevertheless," the authors write, ...
... -- New research suggests that a certain class of drugs ... risk that male patients will be unable to urinate. ... blockage in the body,s air passages, affects an estimated 10 ... class of drugs called "inhaled anticholinergic" medications are used to ...
... 2011More than eight of 10 leaders in health and ... to implement key provisions of the Affordable Care Act ... outlined in the law. Such key provisions include expanding ... insurance exchanges with premium subsidies. Findings are from the ...
... MONDAY, May 23 (HealthDay News) -- U.S. researchers have ... diseases, which are rare, progressive conditions that affect brain ... and bovine spongiform encephalopathy, commonly known as "mad cow ... of the Journal of the American Dietetic Association ...
Cached Medicine News:Health News:New study finds that violence doesn't add to children's enjoyment of TV shows, movies 2Health News:New study finds that violence doesn't add to children's enjoyment of TV shows, movies 3Health News:UTMB researcher receives $3 million NIH grant to study aging in Mexico 2Health News:Patient navigators appear to improve colorectal cancer screening rate in ethnically diverse patients 2Health News:Patient navigators appear to improve colorectal cancer screening rate in ethnically diverse patients 3Health News:Certain COPD Meds Linked to Urinary Troubles in Men 2Health News:States should be allowed to implement key health reform law provisions early, experts say 2Health News:States should be allowed to implement key health reform law provisions early, experts say 3Health News:CDC Warns Against Exposure to 'Mad Cow'-Like Brain Diseases 2
... fume containment system is ... equipment. Even large benchtop ... the Hyperclean 2. The ... unit comes complete with one ...
Reusable shielded cable...
... OIA test features a dual-detection technology to ... for children under age 5 with a ... in just over 15 minutes. This combination ... to decrease costs for unnecessary ancillary testing, ...
... OIA A/B test combines performance equivalence to 14-day ... A or B with a simple, easy-to-use test ... test has all the same procedural steps as ... enable you decrease costs for unnecessary ancillary testing, ...
Medicine Products: